» Articles » PMID: 28557617

Analytic Validation of Immunohistochemical Assays: A Comparison of Laboratory Practices Before and After Introduction of an Evidence-Based Guideline

Overview
Specialty Pathology
Date 2017 May 31
PMID 28557617
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Context: - Laboratories must demonstrate analytic validity before any test can be used clinically, but studies have shown inconsistent practices in immunohistochemical assay validation.

Objective: - To assess changes in immunohistochemistry analytic validation practices after publication of an evidence-based laboratory practice guideline.

Design: - A survey on current immunohistochemistry assay validation practices and on the awareness and adoption of a recently published guideline was sent to subscribers enrolled in one of 3 relevant College of American Pathologists proficiency testing programs and to additional nonsubscribing laboratories that perform immunohistochemical testing. The results were compared with an earlier survey of validation practices.

Results: - Analysis was based on responses from 1085 laboratories that perform immunohistochemical staining. Of 1057 responses, 65.4% (691) were aware of the guideline recommendations before this survey was sent and 79.9% (550 of 688) of those have already adopted some or all of the recommendations. Compared with the 2010 survey, a significant number of laboratories now have written validation procedures for both predictive and nonpredictive marker assays and specifications for the minimum numbers of cases needed for validation. There was also significant improvement in compliance with validation requirements, with 99% (100 of 102) having validated their most recently introduced predictive marker assay, compared with 74.9% (326 of 435) in 2010. The difficulty in finding validation cases for rare antigens and resource limitations were cited as the biggest challenges in implementing the guideline.

Conclusions: - Dissemination of the 2014 evidence-based guideline validation practices had a positive impact on laboratory performance; some or all of the recommendations have been adopted by nearly 80% of respondents.

Citing Articles

Belgian Recommendations for Analytical Verification and Validation of Immunohistochemical Tests in Laboratories of Anatomic Pathology.

Verbeke H, Van Hecke D, Bauraing C, Dierick A, Colleye O, Dalle I Appl Immunohistochem Mol Morphol. 2023; 32(1):1-16.

PMID: 38054253 PMC: 10695338. DOI: 10.1097/PAI.0000000000001165.


HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.

Petri B, Piell K, South Whitt G, Wilt A, Poulton C, Lehman N Cancer Lett. 2021; 518:152-168.

PMID: 34273466 PMC: 8358706. DOI: 10.1016/j.canlet.2021.07.015.


PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.

Keppens C, Dequeker E, Pauwels P, Ryska A, t Hart N, von der Thusen J Virchows Arch. 2020; 478(5):827-839.

PMID: 33275169 PMC: 8099807. DOI: 10.1007/s00428-020-02976-5.


Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry.

MacNeil T, Vathiotis I, Martinez-Morilla S, Yaghoobi V, Zugazagoitia J, Liu Y Biotechniques. 2020; 69(6):460-468.

PMID: 32852223 PMC: 7807291. DOI: 10.2144/btn-2020-0095.


Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.

Lantuejoul S, Damiola F, Adam J Transl Lung Cancer Res. 2020; 9(3):906-916.

PMID: 32676356 PMC: 7354161. DOI: 10.21037/tlcr.2020.03.23.


References
1.
Hardy L, Fitzgibbons P, Goldsmith J, Eisen R, Beasley M, Souers R . Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories. Arch Pathol Lab Med. 2013; 137(1):19-25. DOI: 10.5858/arpa.2011-0676-CP. View

2.
Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010; 134(6):907-22. PMC: 3073033. DOI: 10.5858/134.6.907. View

3.
Fischer A, Schwartz M, Moriarty A, Wilbur D, Souers R, Fatheree L . Immunohistochemistry practices of cytopathology laboratories: a survey of participants in the College of American Pathologists Nongynecologic Cytopathology Education Program. Arch Pathol Lab Med. 2014; 138(9):1167-72. DOI: 10.5858/arpa.2013-0259-CP. View

4.
Fitzgibbons P, Murphy D, Hammond M, Allred D, Valenstein P . Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med. 2010; 134(6):930-5. DOI: 10.5858/134.6.930. View

5.
Fitzgibbons P, Bradley L, Fatheree L, Alsabeh R, Fulton R, Goldsmith J . Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 2014; 138(11):1432-43. DOI: 10.5858/arpa.2013-0610-CP. View